R16, a Novel Amonafide Analogue, Induces G2 Arrest and Apoptosis Via Poisoning Topoisomerase II

Hong Zhu,Min Huang,Yi Chen,Ze‐Hong Miao,Yujun Cai,Jian Ding

IF: 11.2

2007-01-01

Cancer Research

Abstract:AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 770 The naphthalimide derivative amonafide has been selected as an investigational anticancer drug for clinical trials by the National Cancer Institute in the National Institutes of Health. However, its metabolite N-acetyl-amonafide resulting from its N-acetylation on 5’-NH2 of the naphthyl ring by N-acetyltransferase 2 is a major challenging factor for its clinical future as this metabolite may lead to unpredictable, severe toxicity. To eliminate generation of such toxic acetylated metabolite(s), in this study, we substituted the 5’-NH2 with a heterocyclic group to the parent compound amonafide and thus obtained the novel amonafide analogue, 2-(2-dimethylamino)-6-thia-2-aza-benzo [def] chrysene-1, 3-diones (R16). Such substitution totally removed the site acted by N-acetyltransferase 2 and thereby the toxic threats subsequent to its catalytic transformation as on the parent amonafide. On the other hand, R16 also exhibited comparable in vitro and in vivo anticancer activities with amonafide, as shown in a panel of various human tumor cell lines and multidrug resistance cell lines and in mouse S-180 sarcoma and H22 hepatoma models. Mechanistic studies revealed that R16 functioned as a topoisomerase II (Top2) poison via trapping Top2-DNA cleavage complexes and binding to the ATPase domain of human Top2α. Using Top2 catalytic inhibitor aclarubicin, ATM/ATR kinase inhibitor caffeine and Top2-deficient HL-60/MX2 cells, we demonstrated that R16-triggered DNA double-strand breaks, tumor cell cycle arrest and apoptosis were in Top2-dependent manner. These data have uncovered that Top2 is the primary target for R16 in tumor cells and that its prominent antitumor capability is ascribed to the formation of Top2 cleavage complexes. We further explored the effects of R16 on cell cycle and apoptosis. Upon treatment of R16 at low doses, DNA double-strand breaks activated ATM, caused nuclear export of cyclin B1 and consequently resulted in evident G2 arrest in tumor cells. The ATM-Chk2 pathway played a central role in R16-driven G2 arrest. In contrast, higher doses of R16 induced apoptosis by stimulating cytochrome c release from the mitochondria and activating the death receptor pathway. Taken together, our strategy of substituting the 5’-NH2 of amonafide with a heterocyclic group yielded a resulting novel compound R16 with reduced toxicity and comparable anticancer activities. R16 as well as amonafide kills tumor cells, arrests cell cycle in G2 phase and induces apoptosis primarily by targeting Top2. Our data collectively reveal the potential value of R16 for further development as an anticancer drug.